Effects of electrochemotherapy with cisplatin and peritumoral IL-12 gene electrotransfer on canine mast cell tumors: a histopathologic and immunohistochemical study
This work is licensed under the Creative Commons Attribution 4.0 International License.
Campana L, Clover AJP, Valpione S, Quaglino P, Gehl J, Kunte C, et al. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol 2016; 50: 1-12. doi:10.1515/raon-2016-0006CampanaLCloverAJPValpioneSQuaglinoPGehlJKunteCRecommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review201650112doi:10.1515/raon-2016-0006Open DOISearch in Google Scholar
Cemazar M, Tamzali Y, Sersa G, Tozon N, Mir LM, Miklavcic D, et al. Electrochemotherapy in veterinary oncology. J Vet Int Med 2008;22: 826-31. 10.1111/j.1939-1676.2008.0117.xCemazarMTamzaliYSersaGTozonNMirLMMiklavcicDElectrochemotherapy in veterinary oncology2008228263110.1111/j.1939-1676.2008.0117.xOpen DOISearch in Google Scholar
Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315-27. 10.1007/s00262-015-1724-2SersaGTeissieJCemazarMSignoriEKamensekUMarshallGElectrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer20156413152710.1007/s00262-015-1724-2Open DOISearch in Google Scholar
Sedlar A, Dolinsek T, Markelc B, Prosen L, Kranjc S, Bosnjak M, et al. Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radio Oncol 2012; 46: 302-11. 10.2478/v10019-012-0044-9SedlarADolinsekTMarkelcBProsenLKranjcSBosnjakMPotentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity2012463021110.2478/v10019-012-0044-9Open DOISearch in Google Scholar
Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-Ya M, Gojo S, et al. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 2003; 8: 738-45.KishidaTAsadaHItokawaYYasutomiKShin-YaMGojoSElectrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice2003873845Search in Google Scholar
Torrero MN, Henk WG, Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 2006; 12: 257-63. 10.1158/1078-0432.CCR-05-1514TorreroMNHenkWGLiS.Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy2006122576310.1158/1078-0432.CCR-05-1514Open DOISearch in Google Scholar
Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 2008; 423: 319-25. 10.1007/978-1-59745-194-9_24CutreraJTorreroMShiomitsuKMauldinNLiS.Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs20084233192510.1007/978-1-59745-194-9_24Open DOISearch in Google Scholar
Cutrera J, King G, Jones P, Kicenuik K, Gumpel E, Xia X, et al. Safety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions. Curr Gene Ther 2015; 15: 44-54.CutreraJKingGJonesPKicenuikKGumpelEXiaXSafety and efficacy of tumor-targeted interleukin 12 gene therapy in treated and non-treated, metastatic lesions2015154454Search in Google Scholar
Cutrera J, King G, Jones P, Kicenuik K, Gumple E, Xia X, et al. Safe and effective treatment of spontaneous neoplasms with interleukin 12 electrochemo-gene therapy. J Cell Mel Med 2015, 19: 664-75. 10.1111/jcmm.12382CutreraJKingGJonesPKicenuikKGumpleEXiaXSafe and effective treatment of spontaneous neoplasms with interleukin 12 electrochemo-gene therapy2015196647510.1111/jcmm.12382Open DOISearch in Google Scholar
Pavlin D, Cemazar M, Coer A, Sersa G, Pogacnik A, Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiol Oncol 2011; 45: 31-9. 10.2478/v10019-010-0041-9PavlinDCemazarMCoerASersaGPogacnikATozonN.Electrogene therapy with interleukin-12 in canine mast cell tumors20114531910.2478/v10019-010-0041-9Open DOISearch in Google Scholar
Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, et al. Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 electrotransfer of canine mast cell tumors. Vet Comp Oncol 2017; 15: 641-4. 10.1111/vco.12208CemazarMAmbrozic AvgustinJPavlinDSersaGPoliAKrhac LevacicAEfficacy and safety of electrochemotherapy combined with peritumoral IL-12 electrotransfer of canine mast cell tumors201715641410.1111/vco.12208Open DOISearch in Google Scholar
Pavselj N, Preat V. DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J Control Release 2005; 106: 407-15. 10.1016/j.jconrel.2005.05.003PavseljNPreatV.DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse20051064071510.1016/j.jconrel.2005.05.003Open DOISearch in Google Scholar
Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 2011; 48: 147-55. 10.1177/0300985810386469KiupelMWebsterJDBaileyKLBestSDeLayJDetrisacCJProposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior2011481475510.1177/0300985810386469Open DOISearch in Google Scholar
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin- DNA adducts. Chem Rev 1999; 99: 2467-98.JamiesonERLippardSJ.Structure, recognition, and processing of cisplatin- DNA adducts199999246798Search in Google Scholar
Scarfò L, Ghia P. Reprogramming cell death. BCL2 family inhibition in hematological malignancies. Immunol Lett 2013; 155: 36-9. 10.1016/j.imlet.2013.09.015ScarfòLGhiaP.Reprogramming cell death. BCL2 family inhibition in hematological malignancies201315536910.1016/j.imlet.2013.09.015Open DOISearch in Google Scholar
Belehradek J, Orlowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumours in mice. Eur J Cancer 1991; 27: 73-6.BelehradekJOrlowskiSPoddevinBPaolettiCMirLM.Electrochemotherapy of spontaneous mammary tumours in mice199127736Search in Google Scholar
Sersa G, Jarm T, Kotnik T, Coer A, Podkrajek M, Sentjurc M. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 2008; 98: 388-98. 10.1038/sj.bjc.6604168SersaGJarmTKotnikTCoerAPodkrajekMSentjurcM.Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma2008983889810.1038/sj.bjc.6604168Open DOISearch in Google Scholar
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46. 10.1038/nri1001TrinchieriG.Interleukin-12 and the regulation of innate resistance and adaptive immunity200331334610.1038/nri1001Open DOISearch in Google Scholar
Cutrera J, Li S. Passive and active tumor homing cytokine therapy. In: Lustgarten J, Cui Y, Li S, editors. Targeted cancer immune therapy. New York: Springer; 2009. p. 97-113.CutreraJLiS.Passive and active tumor homing cytokine therapyLustgartenJCuiYLiSNew YorkSpringer200997113Search in Google Scholar
Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-85. 10.1158/1078-0432.CCR-07-0776Del VecchioMBajettaECanovaSLotzeMTWesaAParmianiGInterleukin-12: biological properties and clinical application20071346778510.1158/1078-0432.CCR-07-0776Open DOISearch in Google Scholar
Tamzali Y, Borde L, Rols MP, Golzio M, Lyazrhi F, Teissie J. Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases. Equine Vet J 2012; 44: 214-20. 10.1111/j.2042-3306.2011.00425.xTamzaliYBordeLRolsMPGolzioMLyazrhiFTeissieJ.Successful treatment of equine sarcoids with cisplatin electrochemotherapy: a retrospective study of 48 cases2012442142010.1111/j.2042-3306.2011.00425.xOpen DOISearch in Google Scholar
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune provolege and predicts reduced survival. Nat Med 2004; 10: 942-9. 10.1038/nm1093CurielTJCoukosGZouLAlvarezXChengPMottramPSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune provolege and predicts reduced survival200410942910.1038/nm1093Open DOISearch in Google Scholar
Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patient. Int J cancer 2009, 125: 1640-8. 10.1002/ijc.24556ZhouJDingTPanWZhuLYLiLZhengL.Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patient20091251640810.1002/ijc.24556Open DOISearch in Google Scholar
Kim JH, Hur JH, Lee SM, Im KS, Kim NH, Sur JH. Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas. Vet J 2012; 193: 222-7. 10.1016/j.tvjl.2011.10.022KimJHHurJHLeeSMImKSKimNHSurJH.Correlation of Foxp3 positive regulatory T cells with prognostic factors in canine mammary carcinomas2012193222710.1016/j.tvjl.2011.10.022Open DOISearch in Google Scholar
Oh SY, Ryu HH, Yoo DY, Hwang IK, Kweon OK, Kim WH. Evaluation of FOXP3 expression in canine mammary gland tumours. Vet Comp Oncol 2014; 12: 20–8. 10.1111/j.1476-5829.2012.00327.xOhSYRyuHHYooDYHwangIKKweonOKKimWH.Evaluation of FOXP3 expression in canine mammary gland tumours20141220810.1111/j.1476-5829.2012.00327.xOpen DOISearch in Google Scholar
Li Q, Virtuoso LP, Anderson CD, Egilmez NK. Regulatory rebound in IL-12 treated tumors is driven by uncommitted peripheral regulatory T cells. J Immunol 2015, 195: 1293-1300. 10.4049/jimmunol.1403078LiQVirtuosoLPAndersonCDEgilmezNK.Regulatory rebound in IL-12 treated tumors is driven by uncommitted peripheral regulatory T cells1951293130010.4049/jimmunol.1403078Open DOISearch in Google Scholar